Who is sponsoring NCT05492123?

NCT05492123 is sponsored by Hospital Israelita Albert Einstein.

What drugs are being tested in NCT05492123?

Interventions in NCT05492123: Nivolumab 40 mg in 4 ml Injection, Ipilimumab 200 MG in 40 ML Injection, Chemoradiation.

What condition does NCT05492123 study?

NCT05492123 studies Uterine Cervical Neoplasms.

Is NCT05492123 still recruiting?

NCT05492123 is currently recruiting now. Last updated 5 January 2024.

Last reviewed 2024-01-05 · How we verify

NCT05492123

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Nivolumab-ipilimumab and Chemoradiation for Cervical Cancer

Recruiting now Phase 2 Last updated 5 January 2024

What this trial tests

Phase 2 trial testing Nivolumab 40 mg in 4 ml Injection in Uterine Cervical Neoplasms in 112 participants. Currently enrolling.

Timeline

30 August 2022

Primary endpoint
31 December 2026

31 March 2028

Quick facts

Lead sponsor	Hospital Israelita Albert Einstein
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	112
Start date	30 August 2022
Primary completion	31 December 2026
Estimated completion	31 March 2028
Sites	14 locations across Brazil

Drugs / interventions tested

Nivolumab 40 mg in 4 ml Injection — full drug profile →
Ipilimumab 200 MG in 40 ML Injection — full drug profile →
Chemoradiation — full drug profile →

Conditions studied

Uterine Cervical Neoplasms — all drugs for Uterine Cervical Neoplasms →

Sponsor

Hospital Israelita Albert Einstein

Who can join

Adults 18 to 95, female only, with Uterine Cervical Neoplasms. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A total of 112 patients with locally advanced cervical cancer will be randomized 1:1 to standard therapy with cisplatin-based chemoradiation or nivolumab-ipilimumab induction followed by cisplatin-based chemoradiation. The primary outcome will be 3-year disease-free survival.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Advances in cervical cancer: current insights and future directions.
Xu M, Cao C, Wu P, Huang X, et al · · 2025 · cited 55× · PMID 39611440 · DOI 10.1002/cac2.12629
Human papillomavirus associated cervical lesion: pathogenesis and therapeutic interventions.
Ye J, Zheng L, He Y, Qi X. · · 2023 · cited 27× · PMID 37719443 · DOI 10.1002/mco2.368
Cervical cancer treatment update: A Society of Gynecologic Oncology clinical practice statement.
Girda E, Randall LM, Chino F, Monk BJ, et al · · 2023 · cited 18× · PMID 37980766 · DOI 10.1016/j.ygyno.2023.10.017
Recent advances in immunotherapy for cervical cancer.
Ogasawara A, Hasegawa K. · · 2025 · cited 13× · PMID 39888529 · DOI 10.1007/s10147-025-02699-0
The abscopal effect of immune-radiation therapy in recurrent and metastatic cervical cancer: a narrative review.
Ollivier L, Moreau Bachelard C, Renaud E, Dhamelincourt E, et al · · 2023 · cited 6× · PMID 37539054 · DOI 10.3389/fimmu.2023.1201675
The promise of PD1/PDL1 targeted immunotherapy in locally advanced cervical cancer: a game-changer for patients outcome?
Kouhen F, El Ghanmi A, Inghaoun H, Miftah H, et al · · 2025 · cited 3× · PMID 40433369 · DOI 10.3389/fimmu.2025.1573576
Bridging the Gap: Immune Checkpoint Inhibitor as an Option in the Management of Advanced and Recurrent Cervical Cancer in Sub-Saharan Africa.
Okpalanwaka IF, Anazodo FI, Chike-Aliozor ZL, Ekweozor C, et al · · 2024 · cited 2× · PMID 39398762 · DOI 10.7759/cureus.69136
Advancements in the utilization of immune checkpoint inhibitors for the treatment of gynecological tumors.
Su Z, Zhang X, Xu J, Shen Y. · · 2026 · PMID 41983132 · DOI 10.3389/fimmu.2026.1686568

Verify or expand the search:

Other trials of Nivolumab 40 mg in 4 ml Injection

Trials testing the same drug.

NCT06188676 — Multicenter Study of Safety and Efficacy Nivolumab at the Fixed Dose 40 mg (Nivo40) in Combination With Chemo-Immunother · Phase 3 · recruiting
NCT03343665 — Treatment With Nivolumab at the Fixed Dose 40 mg (Nivo40) in Patients With Relapsed/Refractory Hodgkins Lymphoma · Phase 1, PHASE2 · completed

Other recruiting trials for Uterine Cervical Neoplasms

Currently open trials in the same condition.

NCT07305727 — A Radiomic MRI Predictive Model for Response to Concomitant Chemoradiotherapy in Locally Advanced Cervical Cancer · recruiting
NCT07011836 — Video-Based Patient Navigation to Support Cervical Cancer Screening Among Black Women · NA · recruiting
NCT06815939 — Validation of a Lab-free Low-cost Screening Test for Prevention of Cervical Cancer · NA · recruiting
NCT06558682 — Neoadjuvant Therapy in Cervical Cancer · NA · recruiting
NCT06509724 — Comparison of Conventional and Hypofractionated IMRT in High-Risk Cervical Cancer Post-Radical Hysterectomy · Phase 3 · recruiting

Other Hospital Israelita Albert Einstein trials

Trials by the same sponsor.

NCT07447674 — ED Post-Discharge Digital Follow-Up: A Communication Comparison · NA · not yet recruiting
NCT07398222 — Gastric Content in Fasting Volunteers and in Tirzepatide Users: an Observational and Cross-sectional Study · recruiting
NCT07233837 — Hydrogen Peroxide and Ultraviolet Light for Disinfecting Surfaces in Intensive Care Units · NA · recruiting
NCT06726707 — COPPER: A Trial Evaluating Copper-based Products for Incontinence-associated Dermatitis · Phase 2, PHASE3 · withdrawn
NCT07112846 — Prospective Clinical Registry for Evaluation of Exanthematous Infections and Coinfections · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05492123 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hospital Israelita Albert Einstein
Last refreshed: 5 January 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05492123.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing